Smoking and Other Diseases

Slide 1 · Smoking and Other Diseases

Systemic pathology of tobacco smoke, passive exposure, and vaping

Cancer and chronic respiratory injury

Cardiovascular, reproductive, and systemic consequences

Second-hand smoke and EVALI

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning objectives

FOUNDATIONS

Explain how tobacco exposure produces multisystem injury through distinct mechanisms.

Associate smoking with major cancer sites, obstructive lung disease, and vascular events.

Trace pregnancy, systemic, and passive-smoke consequences to the relevant exposure.

Describe vaping-related pulmonary injury without equating vaping with harmlessness.

Slide 3 · Smoking injury extends far beyond the lung

FOUNDATIONS

Tobacco exposure

Malignancy

Multiple organs

Airways

COPD · asthma

Vessels

MI · stroke

Pregnancy

Growth · preterm

Systemic

Diabetes · eye

Bystanders

Passive exposure

Schematic map of established associations; Not scaled by risk

Slide 4 · Exposure categories matter

FOUNDATIONS

Active cigarette smoking: Direct inhalation of combustion products.

Smokeless tobacco: Substantial oral carcinogenic risk, even without inhalation.

Second-hand smoke: Involuntary exposure causing disease in nonsmokers.

Vaping: Inhaled aerosol from an electronic device; Toxicological profile differs from cigarettes.

Slide 5 · Multiple pathways connect exposure to disease

FOUNDATIONS

Chemical exposure

Smoke contains irritants, CO, nicotine and carcinogens

Biological injury

Airway inflammation, impaired oxygen delivery, DNA damage

Organ response

Obstruction, vascular events, fetal effects, malignancy

Mechanistic sequence — simplified conceptual schematic

Slide 6 · Tobacco smoke is a complex toxic mixture

FOUNDATIONS

Approximately 7,000 chemicals in cigarette smoke.

More than 60 components are identified as carcinogenic in the source.

Examples include polycyclic aromatic hydrocarbons, nitrosamines, and aromatic amines.

Individual compounds cause different patterns of epithelial, vascular, and systemic harm.

Slide 7 · Nicotine produces rapid sympathetic effects

FOUNDATIONS

Nicotine exposure

Binds nicotinic acetylcholine receptors

Catecholamine release

Sympathetic neural stimulation

Physiologic response

Heart rate, blood pressure, contractility and output increase

Mechanistic sequence — simplified conceptual schematic

Slide 8 · Carbon monoxide reduces oxygen availability

FOUNDATIONS

CO from smoke

Impaired oxygen transport and use

Tissue hypoxia

Lower effective oxygen availability

Cardiac vulnerability

Supply–demand imbalance is amplified

Mechanistic sequence — simplified conceptual schematic

Slide 9 · Smoking exposure accumulates over time

FOUNDATIONS

Pack-years = packs smoked per day × years of smoking.

Exposure intensity and duration both matter for cumulative harm.

Pack-years describe smoking history; They do not capture all individual susceptibility.

Risk varies by disease and is modified by competing exposures.

Slide 10 · Smoking cessation changes long-term risk

FOUNDATIONS

A marked decline in cardiac mortality risk within five years of cessation.

Lung cancer mortality also declines after quitting, but excess risk persists for decades.

Stopping before pregnancy is associated with normalization of infant birth weight in the source.

Cessation reduces future exposure; It does not erase established pathology immediately.

Slide 11 · Smoking-associated malignancies span many organs

CANCER

Tobacco carcinogenesis

Aerodigestive

Oral · larynx · esophagus

Thorax

Lung / bronchus

Abdominal

Pancreas · liver · stomach

Urinary

Kidney · ureter · bladder

Other epithelial

Colon · cervix

Hematologic

Acute myeloid leukemia

Schematic map of established associations; Not scaled by risk

Slide 12 · Chemical carcinogenesis: Core sequence

CANCER

Procarcinogens

Smoke-borne compounds enter tissues

Metabolic activation

Some CYP intermediates are electrophilic

DNA injury

Adducts and potentially mutagenic repair events

Clonal selection

Acquired oncogenic alterations may accumulate

Mechanistic sequence — simplified conceptual schematic

Slide 13 · Carcinogen–organ relationships are site-specific

CANCER

Table 9.4 lists suspected organ-specific carcinogens rather than definitive single-cause assignments.

Nitrosamines and polycyclic aromatic hydrocarbons recur across exposed sites.

The bladder is linked to aromatic amines, including 4-aminobiphenyl and 2-naphthylamine.

Causal smoking–cancer associations are broader than any one chemical mapping.

Slide 14 · Selected suspected organ-specific carcinogens

CANCER

Site

Compounds identified

Lung / larynx

PAHs; NNK; Polonium-210

Esophagus

NNN

Pancreas

NNK

Bladder

4-Aminobiphenyl; 2-naphthylamine

Slide 15 · Upper aerodigestive cancers share exposure routes

CANCER

The source links tobacco with cancers of the oropharynx, larynx, and esophagus.

Local mucosal contact is relevant for smoked and smokeless tobacco.

The co-exposure to alcohol strengthens the association with oral and laryngeal cancer.

Do not infer equal risk magnitudes for all sites from a common exposure.

Slide 16 · Smokeless tobacco also produces cancer risk

CANCER

Snuff and chewing tobacco are harmful even without inhaled smoke.

Oral carcinogenesis is a major smoking-independent tobacco consequence.

NNK, NNN, and polonium-210 among suspected agents for oral cavity snuff exposure.

Absence of combustion does not imply absence of carcinogens.

Slide 17 · Esophageal and pancreatic cancer associations

CANCER

Esophageal and pancreatic cancers appear’s smoking-related cancer list.

Table 9.4 associates esophageal carcinogenesis with NNN.

The same table lists NNK as a suspected carcinogen associated with pancreatic cancer.

These listings do not establish histologic subtype or molecular specificity.

Slide 18 · Bladder carcinogenesis illustrates systemic delivery

CANCER

Bladder cancer is an established smoking-associated malignancy in the source.

Table 9.4 names 4-aminobiphenyl and 2-naphthylamine as suspected agents.

The organ-specific listing distinguishes this risk from direct airway irritation.

Exposure history remains clinically relevant for urothelial malignancy.

Slide 19 · Other epithelial and hematologic malignancies

CANCER

The textual list includes kidney, cervical, liver, and colon cancers.

Figure 9.10 additionally depicts stomach and upper urinary tract cancers.

Hematopoietic disease includes acute myeloid leukemia in the source illustration.

An organ association does not justify an invented mutation panel or tumor-grade pattern.

Slide 20 · Smoking and alcohol can interact multiplicatively

CANCER

Tobacco exposure

Independent carcinogenic risk

Alcohol exposure

Independent oral/laryngeal risk

Combined exposure

Risk amplification beyond simple addition

Convergent contributors — not a temporal sequence

Slide 21 · Co-exposures complicate cancer attribution

CANCER

Smoking increases the risk of lung cancer associated with asbestos and uranium exposure.

The source describes a roughly tenfold higher lung carcinoma incidence in exposed workers who smoke versus those who do not.

A combined exposure history is needed in occupational clinical assessment.

This example comes from the adjacent lung-cancer discussion.

Slide 22 · Applied example: Hematuria in a smoker

CANCER

Clinical observation

An adult with a long smoking history presents with painless hematuria. A bladder lesion is detected during clinical evaluation.

Pathology interpretation

Smoking is a relevant carcinogenic exposure; Aromatic amines are among suspected bladder-specific tobacco carcinogens. Morphology and clinical workup—not exposure alone—establish diagnosis.

Slide 23 · Pulmonary effects arise from several mechanisms

RESPIRATORY

Inhaled smoke

Small airways

Persistent obstruction

Alveoli

Emphysematous injury

Bronchi

Mucus / bronchitis

Asthma

Exacerbation

Infections

TB and pneumonia

Cilia

Irritant injury

Schematic map of established associations; Not scaled by risk

Slide 24 · Smoking recruits inflammatory cells into the lung

RESPIRATORY

Inhaled toxicants

Airway and alveolar irritation

Leukocyte recruitment

Inflammatory cell accumulation

Local elastase

Proteolytic tissue injury

COPD phenotype

Emphysema and chronic bronchitis

Mechanistic sequence — simplified conceptual schematic

Slide 25 · Protease-mediated injury contributes to emphysema

RESPIRATORY

Inflammatory influx

Elastase production rises locally

Matrix injury

Alveolar septal support is damaged

Loss of walls

Distal air spaces enlarge irreversibly

Functional effect

Reduced elastic recoil / airflow limitation

Mechanistic sequence — simplified conceptual schematic

Slide 26 · Emphysema is an anatomic diagnosis

RESPIRATORY

Emphysema by irreversible enlargement of distal air spaces.

Destruction of alveolar walls accompanies the enlarged spaces.

Smoking-related COPD commonly shows centriacinar emphysema.

Emphysema and chronic bronchitis frequently coexist.

Slide 27 · Centriacinar versus panacinar patterns

RESPIRATORY

Centriacinar

Proximal acinus is preferentially affected.

Predominates in heavy smoking-related COPD.

Typically more pronounced in upper lobes.

Panacinar

Uniform acinar enlargement.

Associated with α₁-antitrypsin deficiency.

Smoking can exacerbate this phenotype.

Slide 28 · Chronic bronchitis: The mucus pathway

RESPIRATORY

Direct smoke irritation

Tracheobronchial mucosal response

Mucus and inflammation

Hypersecretion with persistent airway irritation

Clinical pattern

Chronic productive cough / airflow limitation

Mechanistic sequence — simplified conceptual schematic

Slide 29 · Emphysema and chronic bronchitis coexist

RESPIRATORY

Emphysema

Primary structural locus: Distal air spaces.

Core process: Alveolar wall destruction.

Dominant function: Impaired elastic recoil.

Chronic bronchitis

Primary structural locus: Conducting airways.

Core process: Airway inflammation and mucus.

Dominant symptom: Productive cough.

Slide 30 · Cigarette smoke damages the mucociliary barrier

RESPIRATORY

Formaldehyde and nitrogen oxides are identified as toxic to cilia.

Ciliary injury undermines normal mechanical airway protection.

Mucosal irritation promotes increased mucus production.

These effects complement leukocyte-mediated injury in COPD.

Slide 31 · Smoking exacerbates asthma

RESPIRATORY

The main topic explicitly identifies asthma exacerbation as a tobacco effect.

Smoke acts as an airway irritant and can trigger bronchospastic symptoms.

Asthma is generally associated with variable airflow obstruction.

Coexisting fixed obstruction can complicate asthma–COPD distinction.

Slide 32 · Tuberculosis and respiratory infection risks

RESPIRATORY

Smoking increases the risk of pulmonary tuberculosis.

Figure 9.10 also lists pneumonia and other respiratory effects.

Airway epithelial/ciliary damage provides a plausible impaired-defense context.

The supplied subsection provides associations, not infection-specific risk estimates.

Slide 33 · Clinical distinction: Obstruction patterns

RESPIRATORY

COPD-associated injury

Smoking exposure is a major etiologic factor.

Airway and/or alveolar pathology causes persistent limitation.

Emphysema and chronic bronchitis are frequent manifestations.

Asthma exacerbation

Smoke may act as an acute irritant trigger.

Symptoms often vary with bronchospasm.

A reversible component may overlap with COPD.

Slide 34 · Applied example: Progressive dyspnea

RESPIRATORY

Clinical observation

An older smoker develops persistent exertional breathlessness and a chronic productive cough.

Pathology interpretation

Chronic bronchitis and emphysema can coexist in smoking-related COPD. Mechanisms include mucus hypersecretion, leukocyte recruitment, and proteolytic alveolar injury.

Slide 35 · Smoking increases atherosclerotic and cardiac risk

CARDIOVASCULAR

Vascular / cardiac injury

Platelets

Aggregation

Oxygen supply

CO · lung disease

Cardiac demand

Adrenergic effects

Electrical stability

Lower VF threshold

Atherosclerosis

MI / stroke

Co-risk factors

HTN · cholesterol

Schematic map of established associations; Not scaled by risk

Slide 36 · Atherosclerosis underlies major outcomes

CARDIOVASCULAR

The source links smoking to atherosclerosis and its clinical complications.

Myocardial infarction and stroke are explicitly identified.

Figure 9.10 also includes aortic aneurysm and coronary artery disease.

Multiple biological mechanisms plausibly act together.

Slide 37 · Platelet effects support acute vascular events

CARDIOVASCULAR

Tobacco smoking

Increased platelet aggregation

Prothrombotic tendency

Greater potential for occlusive events

Clinical implication

Atherosclerotic infarction risk increases

Mechanistic sequence — simplified conceptual schematic

Slide 38 · Smoking worsens myocardial oxygen balance

CARDIOVASCULAR

Carbon monoxide

Tissue oxygen delivery decreases

Coexisting lung disease

Oxygen supply can fall further

Sympathetic stimulation

Heart rate / contractility increase

Supply–demand gap

Ischemic vulnerability increases

Convergent contributors — not a temporal sequence

Slide 39 · Cardiac electrophysiology is also affected

CARDIOVASCULAR

A decreased threshold for ventricular fibrillation.

Increased myocardial demand and reduced oxygen supply occur simultaneously.

Smoking-related cardiovascular risk cannot be reduced to plaque burden alone.

This is a pathophysiologic link, not a patient-specific arrhythmia prediction.

Slide 40 · Smoking amplifies traditional cardiac risk factors

CARDIOVASCULAR

Smoking

Exposure-related vascular and oxygen effects

Hypertension

Additional vascular risk

Hypercholesterolemia

Additional atherogenic risk

Joint presence

Multiplicative myocardial infarction risk

Convergent contributors — not a temporal sequence

Slide 41 · Stroke and aortic disease broaden vascular scope

CARDIOVASCULAR

Stroke is named as a major atherosclerotic complication of tobacco use.

The source illustration lists aortic aneurysm and atherosclerosis.

Vascular injury therefore spans cerebral, coronary, and large-vessel territories.

Smoking history matters even when pulmonary symptoms are absent.

Slide 42 · Applied example: Acute coronary syndrome

CARDIOVASCULAR

Clinical observation

A smoker with hypertension and hypercholesterolemia presents with acute chest pain and ischemic ECG changes.

Pathology interpretation

The combination of smoking with hypertension and hypercholesterolemia is described as multiplicative for MI risk; CO-related oxygen impairment and platelet aggregation provide complementary mechanisms.

Slide 43 · Pregnancy and reproductive outcomes

REPRODUCTION

Maternal tobacco exposure

Gestation

Preterm birth

Pregnancy loss

Spontaneous abortion

Placental–fetal

Growth restriction

Fetal brain

Nicotine injury

Pregnancy site

Ectopic pregnancy

Fertility

Reduced in women

Schematic map of established associations; Not scaled by risk

Slide 44 · Maternal smoking harms pregnancy outcome

REPRODUCTION

Spontaneous abortion and preterm delivery are explicitly linked to maternal smoking.

Intrauterine growth restriction is another central adverse outcome.

The source also identifies ectopic pregnancy in its multisystem risk list.

These are distinct outcomes; None should be equated with the others.

Slide 45 · Fetal growth is sensitive to exposure timing

REPRODUCTION

Smoking during pregnancy

Maternal tobacco exposure can restrict fetal growth.

Intrauterine growth retardation is linked to lower birth weight.

Stopped before pregnancy

Normal infant birth weights in this group.

The finding supports cessation before conception, not a guaranteed individual outcome.

Slide 46 · Nicotine is relevant to fetal development

REPRODUCTION

Nicotine crosses beyond the addiction question into developmental toxicity.

The preceding tobacco overview associates nicotine exposure with impaired fetal brain development.

Preterm birth and stillbirth are also identified as nicotine-related concerns.

This does not isolate nicotine as the only harmful constituent of cigarette smoke.

Slide 47 · Additional reproductive and developmental effects

REPRODUCTION

Figure 9.10 includes reduced female fertility and ectopic pregnancy.

Orofacial clefts are listed as associated with maternal smoking.

Male erectile dysfunction is included among tobacco-related outcomes.

Clinical mechanisms are not specified for every listed disease in this subsection.

Slide 48 · Applied example: Antenatal exposure

REPRODUCTION

Clinical observation

A patient planning pregnancy asks whether cessation matters if she has smoked for years.

Pathology interpretation

Maternal smoking with loss, preterm delivery, and intrauterine growth restriction; Stopping before pregnancy is associated with normal birth weight in the cited text.

Slide 49 · Other smoking-linked chronic diseases

OTHER SYSTEMS

Systemic associations

Metabolic

Type 2 diabetes

Immune

Rheumatoid arthritis

Ophthalmic

Macular degeneration

Ocular

Cataract / blindness

Oral

Periodontitis

Skeletal

Hip fractures

Schematic map of established associations; Not scaled by risk

Slide 50 · Type 2 diabetes belongs in the tobacco burden

OTHER SYSTEMS

The source explicitly names type 2 diabetes as smoking-associated.

Figure 9.10 repeats diabetes among chronic diseases linked to smoking.

The topic does not provide a site-specific causal molecular sequence.

Avoid inventing a numerical diabetes risk or biomarker threshold.

Slide 51 · Rheumatoid arthritis and immune effects

OTHER SYSTEMS

Rheumatoid arthritis appears in the source list of smoking-related diseases.

Figure 9.10 includes decreased immune function.

These associations complement respiratory infection vulnerability.

The supplied unit does not specify serologic or histologic subtypes.

Slide 52 · Ophthalmic consequences are not limited to cataracts

OTHER SYSTEMS

Age-related macular degeneration is named in the text.

The associated disease figure lists cataracts and blindness.

Vision-threatening injury is part of the systemic smoking phenotype.

The source does not stratify by clinical stage or ophthalmic imaging criteria.

Slide 53 · Periodontal disease and skeletal injury

OTHER SYSTEMS

Periodontitis is included in the Surgeon General-derived disease map.

Hip fractures are also listed among chronic smoking consequences.

The figure additionally includes overall diminished health.

These endpoints often receive less attention than COPD and cancer.

Slide 54 · Applied example: Multimorbidity

OTHER SYSTEMS

Clinical observation

A long-term smoker has COPD, coronary disease, diabetes, and visual impairment.

Pathology interpretation

These diagnoses span several established smoking-linked systems. The exposure is clinically relevant across organs; Individual disease attribution still requires appropriate clinical assessment.

Slide 55 · Second-hand smoke creates involuntary exposure

PASSIVE SMOKE

Environmental tobacco smoke

Adults

Coronary events

Nonsmokers

Lung cancer

Children

Asthma / infections

Homes

Ongoing exposure

Measurement

Blood cotinine

Policy

Exposure reduction

Schematic map of established associations; Not scaled by risk

Slide 56 · Passive smoke is not biologically inert

PASSIVE SMOKE

The subsection states that environmental tobacco smoke carries many active-smoking risks.

Nonsmokers may acquire smoking-associated lung cancer risk.

Coronary atherosclerosis and fatal myocardial infarction are also highlighted.

Household exposure is particularly concerning for children.

Slide 57 · Passive exposure increases lung cancer risk

PASSIVE SMOKE

Relative risk near 1.3 for exposed versus unexposed nonsmokers.

This is a relative comparison, not a 30% absolute probability of cancer.

The source reports historical U.S. Mortality attributable to second-hand smoke.

Present-day incidence or mortality must not be inferred from the textbook estimate.

Slide 58 · Passive smoke also contributes to cardiac deaths

PASSIVE SMOKE

Coronary atherosclerosis and fatal infarction after passive exposure.

It cites historical U.S. Estimates of 30,000–60,000 associated cardiac deaths annually.

These are source-era estimates, not newly updated counts.

Environmental exposure should be documented in nonsmokers with vascular disease.

Slide 59 · Children are susceptible to household smoke

PASSIVE SMOKE

Children living with smokers have increased respiratory illness frequency.

Asthma is specifically identified among those illnesses.

The household remains a major source of involuntary exposure.

Risk assessment must include cohabitants, not only the patient’s own smoking.

Slide 60 · Cotinine is an exposure marker, not a diagnosis

PASSIVE SMOKE

Inhaled environmental smoke

Nicotine is absorbed

Biotransformation

Cotinine metabolite forms

Blood measurement

Provides evidence of exposure

Clinical interpretation

Does not by itself diagnose a smoking-related disease

Mechanistic sequence — simplified conceptual schematic

Slide 61 · Tobacco control reduces passive exposure

PASSIVE SMOKE

The source reports a greater than 70% reduction in median U.S. Nonsmoker cotinine levels since around 2000.

It attributes the fall substantially to public nonsmoking policies.

Lower population cotinine does not eliminate household exposure.

Population indicators and individual household risks should be distinguished.

Slide 62 · Applied example: Child with asthma

PASSIVE SMOKE

Clinical observation

A child with recurrent wheeze lives with an adult who smokes indoors. The child does not use tobacco.

Pathology interpretation

Environmental tobacco smoke is a clinically relevant exposure. More frequent asthma and respiratory illness in children living with smokers.

Slide 63 · Vaping has a distinct but consequential risk profile

VAPING

Vaped aerosol

Delivery

Nicotine / flavorings

Behavior

Addiction

Airways

Respiratory symptoms

Lung

Chemical injury

Severe form

EVALI

Exposure mixtures

Variable composition

Schematic map of established associations; Not scaled by risk

Slide 64 · Cigarette smoking versus vaping

VAPING

Combustible cigarettes

Inhaled combustion-related toxicants.

Established multisystem chronic disease burden.

CO and numerous identified carcinogens.

Vaping devices

Aerosolized nicotine and other chemicals.

Potentially reduced exposure to some combustion toxins.

Addiction and lung injury remain possible.

Slide 65 · Vaping is not equivalent to harmlessness

VAPING

Aerosolized nicotine and flavoring delivery.

Vaping is used by some long-term smokers and recreational users.

The subsection flags use among adolescents and children.

Reported harms include nicotine addiction, respiratory symptoms, and chemical lung injury.

Slide 66 · EVALI emerged as a severe acute lung injury

VAPING

EVALI means e-cigarette or vaping product use–associated lung injury.

The source dates recognition of the syndrome to 2019.

Thousands of cases and dozens of deaths were reported during the outbreak.

Its pathologic features suggest chemical-induced pneumonitis.

Slide 67 · EVALI: Exposure and tissue response

VAPING

Vaping product

Potentially mixed aerosols and additives

Lung exposure

Chemical-induced epithelial injury

Pathology

Lipid-laden macrophages; Vacuolated pneumocytes

Syndrome

Clinically significant lung injury

Mechanistic sequence — simplified conceptual schematic

Slide 68 · EVALI morphology is suggestive, not specific

VAPING

The source describes lipid-laden alveolar macrophages.

Vacuolated pneumocytes are another reported microscopic finding.

Together they suggest a chemically mediated pneumonitis.

These findings alone do not identify one unique causative substance.

Slide 69 · Vitamin E acetate: Preserve causal uncertainty

VAPING

Many affected patients reported mixtures including cannabinoids and nicotine.

Vitamin E acetate is described as suspected of causing lung damage.

The source does not establish a uniform exposure composition across cases.

Do not misstate association with vitamin E acetate as proven causation for every EVALI case.

Slide 70 · Applied example: Vaping and pneumonitis

VAPING

Clinical observation

A young adult with recent vaping develops severe respiratory symptoms. Lung tissue is reported to contain vacuolated pneumocytes and lipid-laden alveolar macrophages.

Pathology interpretation

Vaping-associated lung injury enters the clinical differential. The microscopy is supportive of chemical injury but is not by itself pathognomonic of EVALI.

Slide 71 · Exposure routes and consequences

SYNTHESIS

Exposure

Illustrative harms

Active smoking

COPD, cancers, myocardial infarction, stroke, fetal effects

Smokeless tobacco

Oral carcinogenesis

Passive smoke

Lung cancer, coronary events, childhood asthma

Vaped aerosols

Nicotine dependence, respiratory symptoms, EVALI

Slide 72 · Mechanism-to-disease synthesis

SYNTHESIS

Carcinogenic compounds → DNA injury → malignancies in multiple organs.

Irritants and leukocyte elastase → airway and alveolar injury → COPD.

Platelet aggregation and oxygen imbalance → atherosclerotic events and arrhythmia susceptibility.

Maternal and passive exposure → fetal and bystander harms, even without direct smoking.

Slide 73 · Clinical synthesis: Exposure history is pathology history

SYNTHESIS

Document active exposure intensity, duration, cessation, and other tobacco products.

Ask about second-hand smoke when patients do not smoke themselves.

Distinguish vaping products and mixtures from combustible tobacco.

Assess systemic manifestations rather than restricting review to the lungs.

Slide 74 · Selected references

SYNTHESIS

Robbins, Cotran & Kumar. Pathologic Basis of Disease. 11th ed. 2026. Chapter 9: Environmental and Nutritional Diseases, pp. 379–381.

Robbins, Cotran & Kumar. Pathologic Basis of Disease. 11th ed. 2026. Chapter 15: The Lung — COPD, emphysema, asthma (cross-reference).

US Department of Health and Human Services. The Health Consequences of Smoking—50 Years of Progress: A Report of the Surgeon General. Source cited in Robbins Figure 9.10.